APA (7th ed.) Citation

S, W., Q, K., S, M., R, R., E, S., D, B., . . . Z, K. (2026). Developing a germline prostate cancer risk test incorporating rare and common variants, to inform clinical decisions: A route to precision oncology. Genome medicine, 18(1), . https://doi.org/10.1186/s13073-026-01640-y

Chicago Style (17th ed.) Citation

S, Wakerell, et al. "Developing a Germline Prostate Cancer Risk Test Incorporating Rare and Common Variants, to Inform Clinical Decisions: A Route to Precision Oncology." Genome Medicine 18, no. 1 (2026). https://doi.org/10.1186/s13073-026-01640-y.

MLA (9th ed.) Citation

S, Wakerell, et al. "Developing a Germline Prostate Cancer Risk Test Incorporating Rare and Common Variants, to Inform Clinical Decisions: A Route to Precision Oncology." Genome Medicine, vol. 18, no. 1, 2026, https://doi.org/10.1186/s13073-026-01640-y.